Skip to content
Safety ProfileEvidence-Based

ARA-290 Side Effects

Honest, evidence-based safety analysis for ARA-290. Frequency data, severity classification, data limitations, and what we genuinely don't know.

Quick Answer

ARA-290 has a generally favorable safety profile, with mild and transient side effects reported in clinical trials. Common side effects include injection site reactions and headache. No serious adverse events related to treatment have been observed. However, long-term safety data is still limited, requiring careful monitoring during use.

→ ARA-290 Dosage→ ARA-290 Benefits→ Full ARA-290 Profile
Table of Contents

Data Context: What We Actually Know

Important: data limitations

Important context: the safety data for ARA-290 comes primarily from phase 2 clinical trials and limited animal studies. Long-term safety and the frequency of rarer side effects are not fully established. The information below represents the best available evidence but should be interpreted with caution.

Side Effects by Severity

MildModerateSevere / Serious
Injection site reactions (redness, discomfort)Mild

Frequency: Common

Rotate injection sites. Usually resolves within a few days.

HeadacheMild

Frequency: Common

Transient. May be managed with over-the-counter pain relievers.

Gastrointestinal discomfort (nausea)Mild

Frequency: Rare

Usually mild and self-resolving.

Contraindications

  • ✕Known hypersensitivity to ARA-290 or any of its components
  • ✕Pregnancy and breastfeeding (limited safety data)
  • ✕Severe cardiovascular disease (precautionary due to potential for tissue effects)

Drug Interactions

No formal pharmacokinetic drug interaction studies have been conducted for most research peptides. The interactions below are theoretical, mechanism-based, or derived from limited case reports.
  • ⚠No significant drug interactions have been reported in clinical trials
  • ⚠Caution with immunosuppressants (theoretical interaction due to anti-inflammatory effects)

Frequently Asked Questions

Is ARA-290 safe?
ARA-290 has a generally favorable safety profile based on phase 2 clinical trials, with mild and transient side effects reported. However, long-term safety data is still limited, requiring careful monitoring during use.
What are the common side effects of ARA-290?
The most common side effects reported in clinical trials include injection site reactions (redness, discomfort) and headache. These are usually mild and transient.
Can ARA-290 cause any serious side effects?
No serious adverse events related to ARA-290 treatment have been observed in phase 2 clinical trials. However, as with any medication, the potential for rare and serious side effects cannot be entirely excluded.
Does ARA-290 affect the immune system?
ARA-290 exhibits anti-inflammatory properties, which may theoretically interact with immunosuppressant medications. Caution is advised when using ARA-290 in combination with immunosuppressants.
Are there any contraindications for using ARA-290?
Contraindications include known hypersensitivity to ARA-290 or any of its components, pregnancy and breastfeeding (due to limited safety data), and severe cardiovascular disease (as a precautionary measure).
Can I take ARA-290 with other medications?
No significant drug interactions have been reported in clinical trials. However, it is essential to inform your healthcare provider about all medications you are taking before starting ARA-290 treatment.

References

  1. 1
    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes(2012)PubMed ↗
  2. 2
    Cibinetide (ARA 290) improves small nerve fiber density and pain in sarcoidosis patients: a randomized controlled trial(2014)PubMed ↗
  3. 3
    The innate repair receptor: a novel concept for tissue protection and repair mediated by the EPO receptor/CD131 heterodimer(2010)PubMed ↗
  4. 4
    Safety of Erythropoietin(2006)PubMed ↗

Last updated: 2026-02-19